{
  "id": 2921153,
  "title": "Symbiotec Pharmalab IPO opens today: Price, dates, lot size and key details",
  "url": "https://urgent.news/2026/08/24/symbiotec-pharmalab-ipo-opens-today-price-dates-lot-size-and-key",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T02:27:58.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-opens-today-price-dates-lot-size-and-key-details/article71381357.ece"
  },
  "original_language": "en",
  "account": null,
  "summary": "Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, is set to open its IPO today with a price band of ₹938 to ₹988 per share, with a face value of ₹2 each. The issue period is from August 24-27, 2026, with a lot size of a minimum of 15 Equity Shares and multiples of 15 thereafter. The total offer size is Rs 1,757 crore, comprising a fresh issue of ₹150 crore and an offer for sale of up to ₹1,607 crore. The IPO quota is allocated as 50% for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for retail investors. The company has received anchor investor support of Rs 526 crore from various mutual funds and financial institutions. Symbiotec Pharmalab specializes in organic chemistry, biotechnology, and complex injectables, and is a global leader in corticosteroid and steroidal-hormone APIs. The proceeds from the IPO will be used for debt payment and general corporate purposes.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Economic Times - Top News",
        "title": "Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?",
        "url": "https://urgent.news/2026/08/24/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk",
        "published": "2026-08-24T00:50:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}